MedicalResearch.com Interview with:
Professor Chris Brightling, NIHR Senior Investigator
Department of Respiratory Sciences
University of Leicester
Leicester, UK
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Risankizumab is an anti-IL23 monoclonal antibody. It is a very effective licensed therapy for plaque psoriasis. IL23 has been implicated in asthma and therefore we chose to study the effect of risankizumab in people with severe asthma.
The time to first asthma worsening was earlier and the frequency of asthma worsenings was higher in those treated with risankizumab versus placebo.
We found that the gene expression of key molecules involved in the response to infection were decreased in airway samples in those treated with risankizumab. It is possible that the increased asthma worsening following risankizumab was related to this suppression of anti-microbial immunity. (more…)